Navigation Links
Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
Date:4/28/2011

e U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) on the design and planned analysis of the ASPIRE trial. Carfilzomib is also being evaluated in the Phase 3 European FOCUS trial, which is designed to support a European registrational filing.  Carfilzomib is also being evaluated in a broad investigator sponsored trial program including first-line multiple myeloma, combination studies, lymphoma and other malignancies.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In Europe, it is estimated that more than 60,000 people are living with multiple myeloma and approximately 21,000 new cases are diagnosed annually.(i) Worldwide, more than 180,000 people are living with multiple myeloma and approximately 86,000 new cases are diagnosed annually.(ii)

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2011 Financial Results on May 5, 2011
2. OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
3. Amylin Pharmaceuticals to Present at the Deutsche Bank 36th Annual Healthcare Conference
4. Idenix Pharmaceuticals Reports First Quarter 2011 Financial Results
5. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
6. Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress
7. Reportlinker Adds The Outlook for Pharmaceuticals in Latin America
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2011
9. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
10. Vanda Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 5, 2011
11. Cumberland Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 4, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 12, 2014 Research and Markets ... http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ...  report to their offering. Global Guidewires sector is ... North America accounts for nearly 35% ... claims approximately 25% (2018). Asia-Pacific ...
(Date:12/15/2014)... TARRYTOWN, N.Y. and BRIDGEWATER, N.J. ... Inc. (NASDAQ: REGN) and Sanofi US (EURONEXT: SAN and ... heart disease organizations to launch Cholesterol Counts , ... know about cholesterol, their numbers, and the risks associated ... to visit www. CholesterolCounts .com to take ...
(Date:12/15/2014)... MARCOS, Texas , Dec. 15, 2014  Stephen ... dot manufacturer Quantum Materials Corp (OTCQB:QTMM), will ... Center for Quantum Materials (RCQM) on December 16th, 2014. ... exploration of exotic nanomaterials in attracting top faculty and ... Rice to collaborate on research. "We ...
Breaking Medicine Technology:Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3
... , , , , , , BANGALORE, India ... unique strategy. This is based on the following,elements: , , ... Sino-Indian focus, - Flexible co-development model availability, ... Experience of early stage life science company product development, - ...
... , , CAMBRIDGE, Mass. , ... it has reached an agreement with the U.S. Food and Drug ... trial for Vascugel®, an investigational new drug for the prevention of ... Special Protocol Assessment (SPA) procedure. Pervasis expects to initiate the study ...
Cached Medicine Technology:Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities 2Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities 3Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 2Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 3Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 4
(Date:12/15/2014)... Health Dialog, a leading provider of ... has received Patient Oriented Accreditation from the National ... Management (DM) Programs for asthma, congestive heart failure, ... and diabetes. This marks the 12th continuous year ... Management (DM) Programs, reaffirming Health Dialog’s focus and ...
(Date:12/15/2014)... Dec. 14, 2014 (HealthDay News) -- Expert pilots process ... explains why they make better decisions during landings, a ... most difficult techniques for pilots to master, and 36 ... fatal crashes occur during final approach and landing. ... and 12 moderately experienced pilots while they were at ...
(Date:12/15/2014)... 2014 Kathy McAfee, America's Marketing Motivator, ... Awards in the category of Best Blog 2014. McAfee ... her weekly career blog Networking Ahead which ... professionals elevate their talent and influence through better networking, ... her book Networking Ahead for Business, has been motivating ...
(Date:12/15/2014)... OR (PRWEB) December 15, 2014 ... seeks to bring attention to restrictive state laws ... position paper on this important area of public ... Laws Can Compromise the Integrity of Independent Review, ... and access of independent peer review determinations can ...
(Date:12/15/2014)... Bacteroides is becoming the indicator of choice for ... prevalent than coliforms, it cannot reproduce in the presence of ... Key Benefits of the new Bacteroides Sewage Screen:, ... Eliminates false positives from coliforms naturally occurring in the environment ... Maintain the same sampling method with results as quick ...
Breaking Medicine News(10 mins):Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... the gold-standard treatment for postoperative and chronic cancer pain ... showing that opiate-based painkillers can stimulate the growth and ... argument and demonstrate how shielding lung cancer cells from ... cell-culture and mouse models. The reports--to be presented ...
... people appear to be fearless, navigating busy sidewalks and ... a cane as a guide. The reason they can ... some circumstances, blindness can heighten other senses, helping individuals ... UCLA Department of Neurology have confirmed that blindness causes ...
... ... , ... Ziosoft®, Inc. http://www.ziosoftinc.com -- a leader in advanced visualization and analysis software for ... marketing, effective November 16., , , , ,Most recently, Royea served as vice president of ...
... , LOUISVILLE, Ky., Nov. 18 ... for its Carewise® Health consumer education and support program ... establishes quality standards for the healthcare industry. , ... education and support accreditation back in 2005, and this ...
... young adults with single-ventricle congenital heart disease who ... sildenafil, a drug used to treat erectile dysfunction ... Hospital of Philadelphia. Single-ventricle defects are ... heart,s ability to pump blood. Examples include tricuspid ...
... , , WASHINGTON, Nov. 18 ... a wholly owned subsidiary of ULLICO Inc., a privately ... Prescription Solutions will provide pharmacy benefit management services to ... union trust funds, union employers and their members with ...
Cached Medicine News:Health News:Common pain relief medication may encourage cancer growth 2Health News:Common pain relief medication may encourage cancer growth 3Health News:UCLA study shows brain's ability to reorganize 2Health News:UCLA study shows brain's ability to reorganize 3Health News:Ziosoft Announces the Appointment of Rob Royea, Vice President, Sales and Marketing 2Health News:SHPS Receives Re-Accreditation from URAC for Consumer Education and Support Program 2Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 2Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: